Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Dutch Bros stock slides 3% as coffee-cost worries return — what investors are watching

Dutch Bros stock slides 3% as coffee-cost worries return — what investors are watching

NEW YORK, December 30, 2025, 15:43 ET — Regular session Dutch Bros Inc. (BROS) shares fell about 3.4% to $62.30 in afternoon trading on Tuesday. The stock has traded between $62.30 and $64.55 after closing at $64.48 on Monday. The move matters for investors because Dutch Bros has been priced as a fast grower, leaving little room for cost surprises as 2025 trading winds down and liquidity thins. A note published earlier on Nasdaq.com said Dutch Bros ended the third quarter with about $706 million of liquidity — cash plus unused borrowing capacity — which can help cushion volatility in
30 December 2025
···
Why Qualys stock is sliding today: QLYS lags cybersecurity peers in late-year trade

Why Qualys stock is sliding today: QLYS lags cybersecurity peers in late-year trade

NEW YORK, December 30, 2025, 15:41 ET — Regular session Qualys Inc shares fell 2.5% to $133.93 in afternoon trading on Tuesday, after dropping as much as 4.2% earlier in the session. The stock closed at $137.34 on Monday. The decline landed as U.S. equities stayed range-bound in holiday-thin conditions, with technology and financial shares among the drags. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. Reuters That matters for Qualys because lighter year-end liquidity can exaggerate moves in single names, especially in software stocks where
30 December 2025
·····
Terns Pharmaceuticals stock slides today, testing the $40 level after December share sale

Terns Pharmaceuticals stock slides today, testing the $40 level after December share sale

NEW YORK, December 30, 2025, 15:30 ET — Regular session. Shares of Terns Pharmaceuticals, Inc. fell 2.8% to $40.34 in afternoon trading on Tuesday, after swinging between $39.99 and $41.98. The pullback puts the stock back around $40, the price used in the company’s recent upsized equity offering — a level traders often watch after a big deal resets supply and demand. That matters now because Terns’ December financing and trial update put new attention on how quickly the biotech can turn early leukemia data into larger studies, while also giving it a much longer cash runway. Biotech shares were
30 December 2025
·····
SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

NEW YORK, December 30, 2025, 15:25 ET — Regular session Scholar Rock Holding Corp (SRRK) slid 3.2% to $43.76 in afternoon trading on Tuesday after opening at $45.18. The stock traded between $45.95 and $43.74. The move matters because Scholar Rock’s near-term valuation still hinges on regulatory timing for apitegromab, its lead drug candidate. he company said in an October update that the FDA classified a third-party manufacturing site in Bloomington, Indiana (formerly Catalent Indiana LLC, now fully owned and operated by Novo Nordisk) as “official action indicated” and that it requested a Type A meeting to discuss resubmitting its
30 December 2025
·····
GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

NEW YORK, December 30, 2025, 15:32 ET — Regular session GRAIL Inc shares were down 3.3% at $84.95 in afternoon trading on Tuesday, after earlier touching $84.77. The early-cancer detection company is trying to turn Galleri — a multi-cancer early detection (MCED) blood test that screens for signals across many cancers from a single draw — into a mainstream part of care. In its most recent quarterly update, Grail said U.S. Galleri revenue rose 28% year-on-year to $32.6 million and test volumes increased 39%, while it anticipated completing a U.S. premarket approval filing in the first quarter of 2026. GRAIL
30 December 2025
···
Upwork stock drops 3% today as UPWK slips below $20 with earnings ahead

Upwork stock drops 3% today as UPWK slips below $20 with earnings ahead

NEW YORK, December 30, 2025, 15:28 ET — Regular session Upwork Inc shares were last down 3.4% at $19.60 on Tuesday, after dipping as low as $19.60 in the session. The stock, valued at about $2.46 billion, was sliding even as the S&P 500 and Nasdaq-100 proxies were only modestly lower. The move matters because Upwork has been trading as a profitability-and-execution story, leaving the stock prone to sharp swings when investors rotate away from smaller growth names. A fall below the $20 level also puts a spotlight on near-term technical support, with traders watching whether the stock can reclaim
30 December 2025
····
Hut 8 stock today: Why HUT is down even as bitcoin edges higher

Hut 8 stock today: Why HUT is down even as bitcoin edges higher

NEW YORK, December 30, 2025, 15:21 ET — Regular session Hut 8 Corp (HUT) shares fell 3.1% to $47.31 in afternoon trading on Tuesday, after moving between $47.18 and $49.26 earlier in the session. About 2.26 million shares had traded. The pullback matters because Hut 8 sits at the intersection of two fast-moving themes: bitcoin-linked equities and the market’s scramble for data centers to run artificial intelligence (AI) workloads. That mix has made the stock prone to sharp, sentiment-driven swings. The broader backdrop has been choppy. U.S. stocks were subdued on Tuesday and trading volumes remained thin in the holiday-truncated
30 December 2025
·····
TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

NEW YORK, December 30, 2025, 15:14 ET — Regular session Shares of TIC Solutions, Inc. (TIC) fell about 3.5% to $10.02 in afternoon trading on Tuesday, underperforming a largely steady U.S. equity market. The stock last closed at $10.38. The decline came in holiday-thin trade as investors recalibrated rate expectations after the Federal Reserve’s December-meeting minutes hit the tape. “At the end of the day, solid corporate profits can make up for a lot of sins,” said Ryan Detrick, chief market strategist at Carson Group. Reuters The slide matters for TIC because investors have been focused on execution rather than
30 December 2025
····
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

NEW YORK, December 30, 2025, 15:16 ET — Regular session Travere Therapeutics Inc shares were down about 3.8% at $37.39 on Tuesday afternoon, extending losses after recent insider-trading disclosures. The stock traded between $37.27 and $39.20, with about 893,000 shares changing hands. (TVTX quote) The selling matters because it lands just weeks before a major regulatory milestone for the rare-disease drugmaker. Traders often react to clusters of insider sales — even when they are planned — as they reassess near-term positioning. Travere, based in San Diego, markets Filspari for a kidney disease called IgA nephropathy, and is seeking an expansion
30 December 2025
·····
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

NEW YORK, December 30, 2025, 2:30 PM ET — Regular session Shares of Catalyst Pharmaceuticals, Inc. fell 3.0% to $23.33 in afternoon trading on Tuesday. The stock has traded between $23.30 and $24.10 so far in the session. The drop matters because trading can get choppy in the final days of the year, when fewer investors are active and price moves can be exaggerated. Mid-cap healthcare names often swing more than the major indexes in that setting. Catalyst fell 1.2% on Monday to close at $24.06, according to MarketWatch data, and it remains well below its June 9 52-week high
30 December 2025
·····
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

NEW YORK, December 30, 2025, 14:30 ET — Regular session Shares of Kymera Therapeutics fell about 3% to $77.94 in afternoon trading on Tuesday, lagging a broader biotech dip. The SPDR S&P Biotech ETF was down about 1.4%, while the iShares Nasdaq Biotechnology ETF slipped about 1.1%. The pullback matters because Kymera has been one of the sector’s higher-volatility names this month, after a surge tied to new clinical data and a subsequent stock sale that increased its share count. With most of its next major readouts still far off, investors have been quick to reprice the stock around financing
30 December 2025
·····
Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

NEW YORK, December 30, 2025, 3:07 PM ET — Regular session Shares of Almonty Industries Inc fell about 3.9% to $8.90 in afternoon trading on Tuesday after giving up an early rise, with the stock swinging between $8.90 and $9.39. The pullback comes as investors focus on tungsten, a hard metal used in munitions, industrial tooling and electronics, at a moment when governments are pushing to secure strategic supply chains. A CBS News report published on Monday said Chief Executive Lewis Black met U.S. officials, including at the White House, before touring Almonty’s Sangdong mine in South Korea and signing
30 December 2025
····
1 … 472 473 474 475 476 … 884

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
BAT share price closes near 52-week high as buyback rolls on ahead of results week

BAT share price closes near 52-week high as buyback rolls on ahead of results week

7 February 2026
British American Tobacco shares closed up 1.2% at 4,609 pence Friday, near a 52-week high. The company disclosed further share buybacks and management share purchases ahead of its Feb. 12 full-year results. BAT bought 121,668 shares for cancellation on Feb. 5. Investors await updates on nicotine alternatives and cash returns.
Go toTop